Humankind Investments LLC Lowers Holdings in McKesson Co. (NYSE:MCK)

Humankind Investments LLC trimmed its position in shares of McKesson Co. (NYSE:MCK) by 5.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,237 shares of the company’s stock after selling 77 shares during the period. Humankind Investments LLC’s holdings in McKesson were worth $705,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Millstone Evans Group LLC purchased a new position in McKesson in the 4th quarter worth approximately $28,000. Synergy Asset Management LLC bought a new stake in shares of McKesson in the 4th quarter worth $32,000. Crews Bank & Trust purchased a new position in shares of McKesson in the fourth quarter worth $33,000. Atala Financial Inc bought a new position in shares of McKesson during the fourth quarter valued at $34,000. Finally, Graney & King LLC purchased a new stake in shares of McKesson during the fourth quarter valued at $38,000. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Brian S. Tyler sold 8,961 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $600.66, for a total value of $5,382,514.26. Following the sale, the chief executive officer now directly owns 69,625 shares in the company, valued at approximately $41,820,952.50. The trade was a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total value of $114,602.92. Following the transaction, the executive vice president now directly owns 1,051 shares of the company’s stock, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,110 shares of company stock worth $10,855,706 in the last 90 days. 0.11% of the stock is currently owned by corporate insiders.

McKesson Stock Performance

MCK opened at $694.12 on Friday. The stock has a market cap of $86.99 billion, a price-to-earnings ratio of 31.78, a price-to-earnings-growth ratio of 1.29 and a beta of 0.53. The firm’s fifty day moving average is $678.24 and its 200 day moving average is $620.91. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $728.48.

McKesson (NYSE:MCK) last released its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, topping analysts’ consensus estimates of $9.83 by $0.29. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The firm had revenue of $90.82 billion during the quarter, compared to analyst estimates of $94 billion. During the same quarter in the prior year, the company posted $6.18 earnings per share. The business’s quarterly revenue was up 18.9% compared to the same quarter last year. On average, equities research analysts predict that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 dividend on an annualized basis and a yield of 0.41%. McKesson’s dividend payout ratio is currently 13.00%.

Analyst Ratings Changes

Several equities analysts have issued reports on MCK shares. Bank of America upped their target price on shares of McKesson from $755.00 to $800.00 and gave the company a “buy” rating in a research note on Friday. Cfra Research downgraded shares of McKesson from a “moderate buy” rating to a “hold” rating in a research report on Friday, April 4th. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. UBS Group upped their price objective on McKesson from $708.00 to $805.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. Finally, Evercore ISI boosted their price target on McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $686.69.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.